Neogenomics Inc. logo

NEO

Neogenomics Inc.

$11.61

Earnings Summary

Revenue
$117.17Mn
Net Profits
$-49.41Mn
Net Profit Margins
-42.17%

Highlights

Revenue:

Neogenomics Inc.’s revenue jumped 1.42% since last year same period to $117.17Mn in the Q1 2022. On a quarterly growth basis, Neogenomics Inc. has generated -6.81% fall in its revenue since last 3-months.

Net Profits:

Neogenomics Inc.’s net profit fell -123.42% since last year same period to $-49.41Mn in the Q1 2022. On a quarterly growth basis, Neogenomics Inc. has generated -18.32% fall in its net profits since last 3-months.

Net Profit Margins:

Neogenomics Inc.’s net profit margin fell -120.3% since last year same period to -42.17% in the Q1 2022. On a quarterly growth basis, Neogenomics Inc. has generated -26.96% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Neogenomics Inc. post its latest quarter earnings

EPS Estimate Current Quarter
-0.22
EPS Estimate Current Year
-0.22

Highlights

EPS Estimate Current Quarter:

Neogenomics Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.22 - a 4.35% jump from last quarter’s estimates.

EPS Estimate Current Year:

Neogenomics Inc.’s earning per share (EPS) estimates for the current year stand at -0.22.

Key Ratios

Key ratios of the Neogenomics Inc. post its Q1 2022 earnings

Earning Per Share (EPS)
-0.2
Return on Assets (ROA)
-0.06
Return on Equity (ROE)
-0.13
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Neogenomics Inc.’s earning per share (EPS) fell -400% since last year same period to -0.2 in the Q1 2022. This indicates that the Neogenomics Inc. has generated -400% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Neogenomics Inc.’s return on assets (ROA) stands at -0.06.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Neogenomics Inc.’s return on equity (ROE) stands at -0.13.

Dividend Per Share (DPS):

Neogenomics Inc. declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-09
-0.23
-0.2
13.04%

Company Information

NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services division serves pharmaceutical clients in clinical trials and drug development. Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Ft. Myers and Tampa, Florida; Aliso Viejo, Carlsbad and Fresno California; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; Rolle, Switzerland, and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.

Organisation
Neogenomics Inc.
Headquarters
Fort Myers, Florida, United States
Employees
1.7K
Industry
Health Services